Anti-CS1 antibodies and antibody drug conjugates
The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.
1. An anti-CS1 antibody comprising six CDRs in which:
V H CDR#1 has an amino acid sequence
(SEQ ID NO: 100)
DYYMA
V H CDR#2 has an amino acid sequence
(SEQ ID NO: 104)
SINYDGSSTYYVDSVKG
V H CDR#3 has an amino acid sequence
(SEQ ID NO: 111)
DRGYYFDY
V L CDR#1 has an amino acid sequence
(SEQ ID NO: 114)
RSSQSLVHSNGNTYLH
V L CDR#2 has an amino acid sequence
(SEQ ID NO: 121)
KVSNRFS
V L CDR#3 has an amino acid sequence
(SEQ ID NO: 123)
SQSTHVPPFT.
2. The antibody of claim 1 which comprises a V H chain corresponding in sequence to SEQ ID NO:8 and a V L chain corresponding in sequence to SEQ ID NO:10.
3. The antibody of claim 1 which comprises a heavy chain corresponding in sequence to SEQ ID NO:34 and a light chain corresponding in sequence to SEQ ID NO:35.
4. The antibody of claim 1 which is an IgG 1 .
5. The antibody of claim 1 which is humanized.
6. The antibody of claim 1 which is an IgG.
7. The antibody of claim 1 which has a kappa light constant region.
8. The antibody of claim 2 which is an IgG 1 .
9. The antibody of claim 2 which has a kappa light constant region.
10. The antibody of claim 1 which has a K D against human CSI of less than about 100 nM.
11. The antibody of claim 1 which has a K D against human CS1 of less than about 10 nM.
12. The antibody of claim 2 which has a K D against human CS1 of less than about 100 nM.
13. The antibody of claim 2 which has a K D against human CS1 of less than about 10 nM.
14. A composition comprising an anti-CS1 antibody and a carrier, wherein the antibody comprises six CDRs in which:
V H CDR#1 has an amino acid sequence DYYMA (SEQ ID NO:100),
V H CDR#2 has an amino acid sequence SINYDGSSTYYVDSVKG (SEQ ID NO:104),
V H CDR#3 has an amino acid sequence DRGYYFDY (SEQ ID NO:111),
V L CDR#1 has an amino acid sequence RSSQSLVHSNGNTYLH (SEQ ID NO:114),
V L CDR#2 has an amino acid sequence KVSNRFS (SEQ ID NO:121), and
V L CDR#3 has an amino acid sequence SQSTHVPPFT (SEQ ID NO:123).
15. The composition of claim 14 which is formulated for pharmaceutical use in humans.
16. The composition of claim 15 which is in unit dosage form.